HCPLive

Hospital Medicine

Latest Headlines

Multiple Sclerosis, Crohn’s Drug Used in HIV Targeted Therapy
Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
Tocilizumab Reduces LDL-C in Patients with Rheumatoid Arthritis
LDL-C was reduced in RA patients who took tocilizumab compared to placebo in a study published in Annals of the Rheumatic Diseases.
Weaning Transplant Patients from Immunosuppressive Drugs
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.
ALLY-1 Results: More Good News on Hep C
As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
Hepatitis C: Interferon's Return Stirs Controversy
The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.
Baclofen: Reducing Alcohol Cravings
In this video interview, Camille Barrault, MD, spoke about the implications her work with baclofen could have for the future of liver disease research at The International Liver Congress 2015, Vienna, Austria.
Liver Disease Takes Toll on the Heart
When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.

Most Popular in Hospital Medicine

Recent Published Journal

$vacMongoViewPlus$ $vAR$